Early Detection Research Network

8 Gene Panel for Barretts Esophagus

Aliases:
This biomarker is also known as:
  • Meltzer 8-marker panel for Esophageal Adenocarcinoma,
  • 8-gene Panel for Barrett's Esophagus,
  • 8 Gene Panel for Barretts Esophagus,

Description…

Eight methylation biomarkers - p16, RUNX3, HPP1 (HGNC name TMEFF2), NELL1, TAC1, SST, AKAP12 and CDH13 - were tested in a restrospective multicenter double-blinded validation study for their accuracy in predicting neoplastic progression in Barretts Esophagus. Hypermethylation of p16, RUNX3 and HPP1 has been show to occur in early Barretts Esophagus-related neoplastic progression and predicts progression risk. Several of the panel (NELL1, TAC1, SST, AKAP12 and CDH13) were also shown to be methylated early and often in Barretts Esophagus-related neoplastic progression.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Accepted
HGNC Name:

Panel Details

The following organs have data associated with this biomarker…

Attributes

Phase: Two
QA State: Under Review

Overview

Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression. In 2005, Meltzer et al reported that hypermethylation of p16, RUNX3, and HPP1 occurs early in Barrett's esophagus-associated neoplastic progression and predicts risk. Later, the group developed a tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features, and also studied methylation levels and frequencies of individual genes using real-time quantitative methylation-specific PCR in 259 endoscopic esophageal biopsy specimens of different histologies. Among ten genes evaluated, five (NELL1, TAC1, SST, AKAP12, and CDH13) were methylated early and often in Barrett's esophagus-associated progression. In these studies, methylation status and levels correlated inversely with mRNA expression levels.

Performance Comment

The findings of this study suggest that this eight-marker panel is more objective and quantifiable and possesses higher predictive sensitivity and specificity than do clinical features, including age.

Supporting Study Data

The following studies/protocols provide evidence supporting 8 Gene Panel for Barretts Esophagus indications for the Esophagus…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

No associated publications found.

No other associated resources found.